Top

Published in:

01-05-2014

Atrial fibrillation in heart failure: catheter and surgical interventional therapies

Authors: Ali Rabah, Oussama Wazni

Published in: Heart Failure Reviews | Issue 3/2014

Abstract

Atrial fibrillation and heart failure commonly coexist in the same patient. Each may adversely affect the other. Atrial fibrillation leads to heart failure exacerbation, left ventricular function deterioration and an increase in thrombo-embolic risk. Therapeutic options targeting atrial fibrillation in heart failure patients include pharmacological and non-pharmacological means. Pharmacological therapy is directed at either rate control using nodal blocking agents or rhythm control using anti-arrhythmic agents, of which the options are limited in patients with heart failure. The landmark AF–CHF trial did not show any benefit of rhythm control strategy as opposed to rate control in patients with heart failure and atrial fibrillation. However, patients in this trial as well as in others used mostly amiodarone for rhythm control. This might have negated any positive effects of achieving normal sinus rhythm. Non-pharmacological therapy both for rate and rhythm control is appealing. This includes AV node ablation for rate control, catheter ablation of atrial fibrillation and surgical therapy of atrial fibrillation. This review will address non-pharmacologic treatment of AF in heart failure patients.

Lloyd-Jones D et al (2009) Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119:e21–e181PubMedCrossRef

Lloyd-Jones DM et al (2004) Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110:1042–1046PubMedCrossRef

Lloyd-Jones D et al (2010) Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 121:e46–e215PubMedCrossRef

Lloyd-Jones DM et al (2002) Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106:3068–3072PubMedCrossRef

Khand AU, Rankin AC, Kaye GC, Cleland JG (2000) Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J 21:614–632PubMedCrossRef

Benjamin EJ et al (1994) Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA, J Am Med Assoc 271:840–844CrossRef

Eijsbouts SCM, Majidi M, Van Zandvoort M, Allessie MA (2003) Effects of acute atrial dilation on heterogeneity in conduction in the isolated rabbit heart. J Cardiovasc Electrophysiol 14:269–278PubMedCrossRef

Kalifa J et al (2003) Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 108:668–671PubMedCrossRef

Li D et al (2001) Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104:2608–2614PubMedCrossRef

10.

Dries DL et al (1998) Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventric. J Am Coll Cardiol 32:695–703PubMedCrossRef

11.

Olsson LG et al (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 47:1997–2004PubMedCrossRef

12.

Crijns HJ et al (2000) Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 21:1238–1245PubMedCrossRef

13.

Carson PE et al. (1993) The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 87, VI102–10

14.

Shinbane JS et al (1997) Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 29:709–715PubMedCrossRef

15.

Clark DM, Plumb VJ, Epstein AE, Kay GN (1997) Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 30:1039–1045PubMedCrossRef

16.

Wyse DG et al (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833PubMedCrossRef

17.

Van Gelder IC et al (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834–1840PubMedCrossRef

18.

Corley SD et al (2004) Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109:1509–1513PubMedCrossRef

19.

Deedwania PC et al (1998) Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department. Circulation 98:2574–2579PubMedCrossRef

20.

Pedersen OD et al (2003) Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study. Card Electrophysiol Rev 7:220–224PubMedCrossRef

21.

Hagens VE et al (2005) Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the RAte Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. Heart Rhythm: Off J Heart Rhythm Soc 2:19–24CrossRef

22.

Roy D et al (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:2667–2677PubMedCrossRef

23.

Bardy GH et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–237PubMedCrossRef

24.

Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA (2000) Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation 101:1138–1144PubMedCrossRef

25.

Wilkoff BL et al (2002) Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA, J Am Med Assoc 288:3115–3123CrossRef

26.

Doshi RN et al (2005) Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 16:1160–1165PubMedCrossRef

27.

Stavrakis S, Garabelli P, Reynolds DW (2012) Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. Europace: Eur Pacing, Arrhythm, Card Electrophysiol: J Work Groups Card Pacing, Arrhythm, Card Cell Electrophysiol Eur Soc Cardiol 14:1490–1497

28.

Khan MN et al (2008) Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 359:1778–1785PubMedCrossRef

29.

Haïssaguerre M et al (1998) Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659–666PubMedCrossRef

30.

Jalife J (2003) Rotors and spiral waves in atrial fibrillation. J Cardiovasc Electrophysiol 14:776–780PubMedCrossRef

31.

Haïssaguerre M et al (2005) Catheter ablation of long-lasting persistent atrial fibrillation: clinical outcome and mechanisms of subsequent arrhythmias. J Cardiovasc Electrophysiol 16:1138–1147PubMedCrossRef

32.

Wazni OM et al (2005) Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA, J Am Med Assoc 293:2634–2640CrossRef

33.

Pappone C et al (2006) A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 48:2340–2347PubMedCrossRef

34.

Noheria A, Kumar A, Wylie JV, Josephson ME (2008) Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med 168:581–586PubMedCrossRef

35.

Cappato R et al (2010) Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 3:32–38PubMedCrossRef

36.

Chen MS et al (2004) Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol 43:1004–1009PubMedCrossRef

37.

Hsu L-F et al (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351:2373–2383PubMedCrossRef

38.

De Potter T et al (2010) Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation. Europace: Eur Pacing, Arrhythm, Card Electrophysiol: J Work Groups Card Pacing, Arrhythm Card Cell Electrophysiol Eur Soc Cardiol 12:24–29

39.

Lutomsky BA et al (2008) Catheter ablation of paroxysmal atrial fibrillation improves cardiac function: a prospective study on the impact of atrial fibrillation ablation on left ventricular function assessed by magnetic resonance imaging. Europace: Eur Pacing, Arrhyth, Card Electrophysiol: J Work Groups Card Pacing, Arrhythm, Card Cell Electrophysiol Eur Soc Cardiol 10:593–599

40.

MacDonald MR et al (2011) Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart (Br Card Soc) 97:740–747CrossRef

41.

Dagres N et al (2011) Catheter ablation for atrial fibrillation in patients with left ventricular systolic dysfunction. A systematic review and meta-analysis. J Card Fail 17:964–970PubMedCrossRef

42.

Jones DG et al (2013) A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 61:1894–1903PubMedCrossRef

43.

Swank AM et al (2012) Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training. Circ Heart Fail 5:579–585PubMedCentralPubMedCrossRef

44.

Marrouche NF, Brachmann J (2009) Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF)—study design. Pacing Clin Electrophysiol: PACE 32:987–994PubMedCrossRef

45.

Grigioni F et al (2002) Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and long-term outcome. J Am Coll Cardiol 40:84–92PubMedCrossRef

46.

Quader MA et al (2004) Does preoperative atrial fibrillation reduce survival after coronary artery bypass grafting? Ann Thorac Surg 77:1514–1522 discussion 1522–1524 PubMedCrossRef

47.

Rabkin DG et al (2004) Load dependence of cardiac output in biventricular pacing: right ventricular pressure overload in pigs. J Thorac Cardiovasc Surg 127:1713–1722PubMedCrossRef

48.

Gillinov AM et al (2005) The Cox maze procedure in mitral valve disease: predictors of recurrent atrial fibrillation. J Thorac Cardiovasc Surg 130:1653–1660PubMedCrossRef

49.

Stulak JM et al (2006) Left ventricular dysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-maze procedure significantly improves systolic function and functional status. Ann Thorac Surg 82:494–500 discussion 500–1PubMedCrossRef

50.

Ad N, Henry L, Hunt S (2011) The impact of surgical ablation in patients with low ejection fraction, heart failure, and atrial fibrillation. Eur J Cardio-Thorac Surg: Off J Eur Assoc Cardio-Thorac Surg 40:70–76CrossRef

Title: Atrial fibrillation in heart failure: catheter and surgical interventional therapies
Authors: Ali Rabah
Oussama Wazni
Publication date: 01-05-2014
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 3/2014
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-013-9411-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Atrial fibrillation in heart failure: catheter and surgical interventional therapies

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Combined management of atrial fibrillation and heart failure: case studies

Atrial fibrillation in heart failure: drug therapies for rate and rhythm control

Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure

Atrial fibrillation and heart failure: intersecting populations, morbidities, and mortality

Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases

Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page